IOL Chemicals & Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• IOL Chemicals & Pharmaceuticals Ltd reported a 2.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 7.9%.
• Its expenses for the quarter were up by 4.0% QoQ and 5.5% YoY.
• The net profit decreased 11.7% QoQ and increased 56.5% YoY.
• The earnings per share (EPS) of IOL Chemicals & Pharmaceuticals Ltd stood at 1.02 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

IOL Chemicals & Pharmaceuticals Ltd is a chemical and pharmaceutical manufacturing company based in India. The company is known for its production of Active Pharmaceutical Ingredients (APIs) and specialty chemicals, catering to various therapeutic categories. IOL Chemicals & Pharmaceuticals Ltd is a significant player in the pharmaceutical industry, with a global presence. As of the information available up to October 2023, there are no recent major developments or changes in the company's core business operations. The company's performance and market standing are typically influenced by trends in the pharmaceutical and chemical industries, regulatory changes, and global market dynamics.

Revenue

For the second quarter of the fiscal year 2026 (Q2FY26), IOL Chemicals & Pharmaceuticals Ltd reported a total income of ₹574.41 crores. This represents a quarter-over-quarter (QoQ) increase of 2.7% from the ₹559.06 crores recorded in the first quarter of fiscal year 2026 (Q1FY26). On a year-over-year (YoY) basis, the total income showed a growth of 7.9% compared to ₹532.18 crores in the second quarter of fiscal year 2025 (Q2FY25). The steady increase in revenue over the quarters and years indicates the company’s consistent performance in generating income. This positive trend in total income highlights the company’s capacity to sustain growth in its core operational areas.

Profitability

The profitability of IOL Chemicals & Pharmaceuticals Ltd in Q2FY26 was influenced by several key factors. The Profit Before Tax (PBT) for the quarter was ₹40.49 crores, reflecting an 11.0% decline on a QoQ basis from ₹45.51 crores in Q1FY26. However, there was a significant YoY increase of 56.1% from the ₹25.94 crores recorded in Q2FY25. The Profit After Tax (PAT) for Q2FY26 was ₹29.97 crores, a decrease of 11.7% QoQ from ₹33.93 crores in Q1FY26, but a robust YoY growth of 56.5% from ₹19.15 crores in Q2FY25. The PAT margin reflects the company’s ability to manage its cost structure and tax liabilities effectively. The Earnings Per Share (EPS) for Q2FY26 was reported at ₹1.02, down 12.1% QoQ from ₹1.16 and a marked decline of 68.7% YoY from ₹3.26 in Q2FY25. Despite the QoQ decline in profitability metrics, the YoY growth suggests an overall improvement in the financial health as compared to the previous year.

Operating Metrics

The operating metrics of IOL Chemicals & Pharmaceuticals Ltd for Q2FY26 indicate an increase in total expenses to ₹533.92 crores, which is a 4.0% rise from ₹513.55 crores reported in Q1FY26. Compared to Q2FY25, there was a 5.5% increase from ₹506.24 crores. The rise in expenses could be attributed to various factors, including increased production costs or operational expansion. The tax expense for Q2FY26 was ₹10.52 crores, showing a decrease of 9.2% QoQ from ₹11.58 crores and a 54.9% increase YoY from ₹6.79 crores in Q2FY25. These metrics provide an overview of the company's cost management and tax strategies over the reported periods. The data reflects the company’s ability to manage its operational costs while navigating external economic factors impacting its financial performance.